Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life

Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle

Redesigned brain receptor drugs show promise for depression

The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold

Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy

The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial

FDA nod to first-ever treatment for fatal pediatric Menkes disease

GSK reports breakthrough results in chronic hepatitis B trials

World First: Heart bypass without opening the chest achieved by NIH and Emory Team

Rapid-acting ADHD treatment Azstarys now approved in China

ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood